{"api":"v1","generated_at":"2026-10-02T17:47:39.678Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/api-magentlab-com-api-calc-icc-pmf-3ca82f","pinned_page":"https://tollindex.com/e/api-magentlab-com-api-calc-icc-pmf-3ca82f/at/2026-10-02T12-31Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-10-02T12:31:46.748Z","snapshot_stamp":"2026-10-02T12-31Z","endpoint":{"slug":"api-magentlab-com-api-calc-icc-pmf-3ca82f","canonical_url":"https://api.magentlab.com/api/calc/icc_pmf","resource":"https://api.magentlab.com/api/calc/icc_pmf","http_method":"POST","type":"http","x402_version":2,"registries":["cdp"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"ICC 2022 prefibrotic and overt PMF (Arber 2022). Diagnosed iff 3 majors and ≥1 minor. Majors: megakaryocyte morphology, not another myeloid neoplasm, JAK2/CALR/MPL or other clone or no reactive fibrosis. Minors: anemia not from comorbidity, WBC ≥11e9/L, splenomegaly, LDH above ULN; leukoerythroblastosis counts only in overt PMF. Not DIPSS, MIPSS70, WHO 5th, or post-PV/post-ET MF. magent does not read fibrosis grade or sequence drivers. Not a diagnosis or medical device.","service_name":"magent","declared_category":null,"declared_tags":["icc-2022","pmf","myelofibrosis","hematology","calculator"],"route_template":null,"registry_updated":"2026-09-28T15:09:53.437Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"calc icc pmf","category":"other","first_observed_by_toll":"2026-09-28T13:51:25.436Z","last_observed_by_toll":"2026-10-02T12:31:46.748Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"cdp","at":"2026-09-28T13:51:25.437Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.005 USDC","amount_units":0.005,"decimals_known":true,"pay_to":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","scheme":"exact"}],"counters":{"observed_at":"2026-10-02T12:31:46.748Z","calls_30d":1,"unique_payers_30d":1,"last_called_at":"2026-09-28T15:09:53.315Z"},"validation":{"latest":{"observed_at":"2026-10-02T14:07:23.404Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-10-02"},"uptime":[{"days":7,"observed":6,"passed":6,"ratio":1},{"days":30,"observed":6,"passed":6,"ratio":1},{"days":90,"observed":6,"passed":6,"ratio":1}],"history_90d":[{"observed_at":"2026-10-02T14:07:23.404Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-02","state_changed":false},{"observed_at":"2026-10-01T07:11:14.582Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-01","state_changed":false},{"observed_at":"2026-09-30T06:28:29.087Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-30","state_changed":false},{"observed_at":"2026-09-29T18:48:26.706Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-29","state_changed":false},{"observed_at":"2026-09-28T16:54:49.191Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-28","state_changed":false},{"observed_at":"2026-09-28T16:40:50.231Z","state":"pass","failed_checks":[],"run_id":"new-after-daily-2026-09-28","state_changed":true}]},"seller":{"wallet":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","page":"https://tollindex.com/seller/0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","endpoints":844,"hosts":1},"reports":0,"registry_record":{"cdp":[{"tags":["icc-2022","pmf","myelofibrosis","hematology","calculator"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2","paymentFlow":"upfront","resourceUrl":"https://api.magentlab.com/api/calc/icc_pmf","assetTransferMethod":"eip3009"},"payTo":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","amount":"5000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":600}],"quality":{"lastCalledAt":"2026-09-28T15:09:53.315Z","l30DaysTotalCalls":1,"l30DaysUniquePayers":1},"resource":"https://api.magentlab.com/api/calc/icc_pmf","extensions":{"bazaar":{"info":{"input":{"body":{"items":[{"phenotype":"pre","splenomegaly":false,"ldh_above_uln":false,"not_other_myeloid":true,"leukocytosis_ge_11":false,"anemia_not_comorbid":true,"clonal_or_no_reactive":true,"leukoerythroblastosis":false,"megakaryocyte_morphology":true},{"phenotype":"pre","splenomegaly":false,"ldh_above_uln":false,"not_other_myeloid":true,"leukocytosis_ge_11":false,"anemia_not_comorbid":true,"clonal_or_no_reactive":true,"leukoerythroblastosis":false,"megakaryocyte_morphology":true}]},"type":"http","method":"POST"},"output":{"type":"json","example":{"path":"/api/calc/icc_pmf","count":2,"items":[{"formula":"icc_pmf","citation":{"id":"arber-2022","doi":"10.1182/blood.2022015850","pmid":"35767897","title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","source":"Blood. 2022;140(11):1200-1228","authors":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Bennett JM, de la Fuente J, et al."},"criteria":[{"met":true,"factor":"megakaryocyte_morphology"},{"met":true,"factor":"not_other_myeloid"},{"met":true,"factor":"clonal_or_no_reactive"},{"met":true,"factor":"anemia_not_comorbid"},{"met":false,"factor":"leukocytosis_ge_11"},{"met":false,"factor":"splenomegaly"},{"met":false,"factor":"ldh_above_uln"},{"met":false,"factor":"leukoerythroblastosis"},{"met":true,"factor":"three_majors"},{"met":true,"factor":"minor_count_ge_1"}],"diagnosed":true,"phenotype":"pre","disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","major_count":3,"minor_count":1,"splenomegaly":false,"ldh_above_uln":false,"not_other_myeloid":true,"formula_expression":"diagnosed iff three majors and minor_count ≥ 1; majors are megakaryocyte_morphology, not_other_myeloid, and clonal_or_no_reactive; minor_count is anemia_not_comorbid + leukocytosis_ge_11 + splenomegaly + ldh_above_uln + leukoerythroblastosis only when phenotype is overt (Arber 2022 ICC pre-PMF and overt PMF). Not DIPSS. Not WHO 5th. Not post-PV/post-ET myelofibrosis","leukocytosis_ge_11":false,"anemia_not_comorbid":true,"clonal_or_no_reactive":true,"leukoerythroblastosis":false,"megakaryocyte_morphology":true},{"formula":"icc_pmf","citation":{"id":"arber-2022","doi":"10.1182/blood.2022015850","pmid":"35767897","title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","source":"Blood. 2022;140(11):1200-1228","authors":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Bennett JM, de la Fuente J, et al."},"criteria":[{"met":true,"factor":"megakaryocyte_morphology"},{"met":true,"factor":"not_other_myeloid"},{"met":true,"factor":"clonal_or_no_reactive"},{"met":true,"factor":"anemia_not_comorbid"},{"met":false,"factor":"leukocytosis_ge_11"},{"met":false,"factor":"splenomegaly"},{"met":false,"factor":"ldh_above_uln"},{"met":false,"factor":"leukoerythroblastosis"},{"met":true,"factor":"three_majors"},{"met":true,"factor":"minor_count_ge_1"}],"diagnosed":true,"phenotype":"pre","disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","major_count":3,"minor_count":1,"splenomegaly":false,"ldh_above_uln":false,"not_other_myeloid":true,"formula_expression":"diagnosed iff three majors and minor_count ≥ 1; majors are megakaryocyte_morphology, not_other_myeloid, and clonal_or_no_reactive; minor_count is anemia_not_comorbid + leukocytosis_ge_11 + splenomegaly + ldh_above_uln + leukoerythroblastosis only when phenotype is overt (Arber 2022 ICC pre-PMF and overt PMF). Not DIPSS. Not WHO 5th. Not post-PV/post-ET myelofibrosis","leukocytosis_ge_11":false,"anemia_not_comorbid":true,"clonal_or_no_reactive":true,"leukoerythroblastosis":false,"megakaryocyte_morphology":true}]}},"iconUrl":"https://api.magentlab.com/favicon.ico"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"body":{"type":"object","required":["items"],"properties":{"items":{"type":"array","items":{"type":"object","required":["phenotype","megakaryocyte_morphology","not_other_myeloid","clonal_or_no_reactive","anemia_not_comorbid","leukocytosis_ge_11","splenomegaly","ldh_above_uln","leukoerythroblastosis"],"properties":{"phenotype":{"enum":["pre","overt"],"type":"string","description":"pre (prefibrotic/early PMF) or overt (overt fibrotic PMF) as assigned by the caller (Arber 2022 ICC). Required. magent does not assign phenotype from a biopsy."},"splenomegaly":{"type":"boolean","description":"Palpable splenomegaly as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not examine the spleen."},"ldh_above_uln":{"type":"boolean","description":"LDH above the institutional upper limit of normal as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not assay LDH."},"not_other_myeloid":{"type":"boolean","description":"Does not meet ICC/WHO criteria for BCR::ABL1-positive CML, PV, ET, MDS, or another defined myeloid neoplasm, as assigned by the caller (Arber 2022 ICC PMF major). true or false. magent does not diagnose those neoplasms."},"leukocytosis_ge_11":{"type":"boolean","description":"Leukocytosis ≥11 × 10^9/L as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not assay WBC."},"anemia_not_comorbid":{"type":"boolean","description":"Anemia not attributed to a comorbid condition, as assigned by the caller (Arber 2022 ICC PMF minor). true or false. magent does not assay hemoglobin."},"clonal_or_no_reactive":{"type":"boolean","description":"JAK2, CALR, or MPL mutation, or another clonal marker, or absence of reactive bone-marrow fibrosis, as assigned by the caller (Arber 2022 ICC PMF major). true or false. magent does not sequence."},"leukoerythroblastosis":{"type":"boolean","description":"Leukoerythroblastosis as assigned by the caller (Arber 2022 ICC overt-PMF minor). Counts toward minor_count only when phenotype is overt; echoed but not counted when phenotype is pre. true or false. magent does not read a smear."},"megakaryocyte_morphology":{"type":"boolean","description":"Megakaryocytic proliferation and atypia for the chosen phenotype, as assigned by the caller (Arber 2022 ICC PMF major). For pre: without reticulin fibrosis grade >1, with increased age-adjusted cellularity, granulocytic proliferation, and often decreased erythropoiesis. For overt: accompanied by reticulin and/or collagen fibrosis grade 2 or 3. true or false. magent does not read a biopsy."}}},"maxItems":25,"minItems":1}},"additionalProperties":false},"type":{"type":"string","const":"http"},"method":{"type":"string","const":"POST"},"headers":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}}},"description":"ICC 2022 prefibrotic and overt PMF (Arber 2022). Diagnosed iff 3 majors and ≥1 minor. Majors: megakaryocyte morphology, not another myeloid neoplasm, JAK2/CALR/MPL or other clone or no reactive fibrosis. Minors: anemia not from comorbidity, WBC ≥11e9/L, splenomegaly, LDH above ULN; leukoerythroblastosis counts only in overt PMF. Not DIPSS, MIPSS70, WHO 5th, or post-PV/post-ET MF. magent does not read fibrosis grade or sequence drivers. Not a diagnosis or medical device.","lastUpdated":"2026-09-28T15:09:53.437Z","serviceName":"magent","x402Version":2}]}}